r-hGH
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Turner's Syndrome
Conditions
Turner's Syndrome
Trial Timeline
Feb 29, 1992 → Aug 31, 2010
NCT ID
NCT01066052About r-hGH
r-hGH is a approved stage product being developed by Merck for Turner's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01066052. Target conditions include Turner's Syndrome.
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01066052 | Approved | Completed |
Competing Products
1 competing product in Turner's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | Novo Nordisk | Phase 1 | 21 |